A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)

Nagpal, Manish; Nagpal, Kamal; Nagpal, P. N.
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p437
Academic Journal
journal article
Wet age-related macular degeneration and diabetic retinopathy are pathological consequences of vascular endothelial growth factor (VEGF) release as a reaction to deficiency of oxygen and nutrients in the macular cells. Conventional treatment modalities have been constrained by limited success. Convincing evidence exists that targeting VEGF signaling is a significant approach for the therapy of these ocular angiogenesis-dependent disorders. We have come a long way since the approval of the first angiogenesis inhibitors in medicine. The clinical use of these drugs has provided enormous tempo to clinical and pharmacological research. It has also significantly altered patient outcome and expectations. In the following brief, we will discuss the development and emergence of these drugs as well as the anticipated future course based on evidence.


Related Articles

  • Retinal Treatments Focus On Pharmaceuticals. Regillo, Carl // Review of Ophthalmology;May2006 Part 1 of 2, Vol. 13 Issue 5, p44 

    The article discusses studies concerning pharmaceutical interventions for retinal conditions presented at the 2006 Association for Research in Vision and Ophthalmology meeting. Retinal surgeons and researchers keep on testing the new anti-vascular endothelial growth factors and anti-inflammatory...

  • Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Fang Lu; Ron Adelman // Graefe's Archive of Clinical & Experimental Ophthalmology;Feb2009, Vol. 247 Issue 2, p171 

    Abstract Background  Vascular endothelial growth factor (VEGF) is an important stimulator of choroidal neovascularization (CNV). Bevacizumab (Avastin), ranibizumab (Lucentis) and pegaptanib sodium (Macugen) are anti-VEGF medications that have been used in the treatment of CNV. The purpose...

  • Anti-VEGF therapy: comparison of current and future agents. Pieramici, D. J.; Rabena, M. D. // Eye;Oct2008, Vol. 22 Issue 10, p1330 

    With the identification of vascular endothelial growth factor (VEGF) and the confirmation of its pathophysiologic link to retinal and choroidal angiogenesis, numerous agents have been designed to inhibit its activity. It is noteworthy that anatomic and visual benefits have been associated with...

  • Anti-VEGFs equivalent in IVAN2, GEFAL trials. Charters, Lynda; Kodjikian, Laurent // Ophthalmology Times;6/15/2013, Vol. 38 Issue 12, p8 

    The article discusses the findings of two randomized clinical trials which revealed the similar efficacy of bevacizumab and ranibizumab, two anti-vascular endothelial growth factor (VEGF) drugs for age-related macular degeneration (AMD) treatment, for improving vision. It describes the procedure...

  • For DME, One Size Does Not Fit All. Bethke, Walter // Review of Ophthalmology;Aug2011, Vol. 18 Issue 8, p34 

    The article discusses treating patients with diabetic macular edema (DME). It mentions the use of lasers and anti-vascular endothelial growth factor drugs in treating DME. In terms of agents that are available, physicians started to include anti-VEGF drugs including ranibizumab (Lucentis) and...

  • Anti-vascular Endothelial Growth Factor Drugs for Diabetic Retinopathy. Forte, Raimondo; Querques, Giuseppe; Cennamo, Gilda; Bonavolontà, Paola; Pascotto, Arduino; Souied, Eric H. // Current Medical Literature: Diabetes;2012, Vol. 29 Issue 4, p109 

    The article examines the existing literature on the use of anti-vascular endothelial growth factor (VEGF) drugs in diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). It presents a definition of DME and its pathophysiology. It describes VEGF inhibitors, including...

  • When Anti-VEGF Treatment Fails. Gallemore, Ron P.; Nguyen, David // Review of Ophthalmology;Mar2008, Vol. 15 Issue 3, p101 

    The article focuses on the management of treatment failures related to Anti-Vascular Endothelial Growth Factor (VEGF) Therapy for the treatment of patients with wet macular degeneration. Failures with the Macugen therapy required a switch to an alternative anti-VEGF agent with a response rate...

  • Anti-VEGF for CNV: Questions Remain. Stephenson, Michelle // Review of Ophthalmology;Sep2011, Vol. 18 Issue 9, p42 

    The article focuses on the efficacy of bevacizumab (Avastin) and ranibizumab (Lucentis) for the treatment of corneal neovascularization. According to associate professor at Rocky Mountain Lions Eye Institute Richard Davidson, anti-vascular endothelial growth factor (anti-VEGF) can be used in...

  • Intravitreal anti-VEGF drugs are step forward in AMD management. Charters, Lynda // Ophthalmology Times;12/15/2005, Vol. 30 Issue 24, p1 

    The article reports on the success of the development of the anti-vascular endothelial growth factor treatments for age-related macular degeneration (AMD). According to retina specialist Charles Schepens, the introduction of pegaptanib sodium and the clinical trial data of ranibizumab indicated...

  • Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Meyer, C. H.; Holz, F. G. // Eye;Jun2011, Vol. 25 Issue 6, p661 

    Three anti-vascular endothelial growth factor (VEGF) therapies are currently used for the treatment of patients with wet age-related macular degeneration (AMD): pegaptanib, ranibizumab, and bevacizumab. Ranibizumab is an antibody fragment approved for the treatment of wet AMD. Bevacizumab is a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics